CN201692349U - Amlodipine polypharmacy valsartan capsule tablet - Google Patents
Amlodipine polypharmacy valsartan capsule tablet Download PDFInfo
- Publication number
- CN201692349U CN201692349U CN2010202391149U CN201020239114U CN201692349U CN 201692349 U CN201692349 U CN 201692349U CN 2010202391149 U CN2010202391149 U CN 2010202391149U CN 201020239114 U CN201020239114 U CN 201020239114U CN 201692349 U CN201692349 U CN 201692349U
- Authority
- CN
- China
- Prior art keywords
- amlodipine
- valsartan
- polypharmacy
- sheet
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Amlodipine polypharmacy valsartan capsule tablet belongs to the technical field of pharmaceutical dosage form structures and comprises a capsule shell and pharmaceutical preparation arranged in the capsule shell, wherein the pharmaceutical preparation comprises single prescription Amlodipine tablets and polypharmacy valsartan tablets. The Amlodipine polypharmacy valsartan capsule tablet is convenient to be taken and simple to be prepared, does not need secondary tabletting, and only a common tabletting machine is needed.
Description
Technical field
This utility model relates to a kind of pharmaceutical formulation structure, is specifically related to the capsule sheet that a kind of amlodipine, compound valsartan are made, and belongs to field of pharmaceutical preparations.
Background technology
In numerous antihypertensive drug, the present market share of calcium antagonist ranks first, and wherein amlodipine was sure to occupy first of depressor always from 1999.Amlodipine Besylate Tablet is the calcium ion blocker, has the advantages that the hypotensive effect time is long, fluctuation of blood pressure is little, and this medicine is removed with metabolite simultaneously, so renal insufficiency does not have obvious influence to its pharmacokinetics.Because of its long-term safety, taking convenience, advantage such as untoward reaction is few, clinical practice in recent years is increasing, is the ideal antihypertensive drugs of light moderate hypertension patient.Its main mechanism of action is stronger to the blood vessel selectivity, but diastole coronary vasodilator and whole body blood vessel, and coronary blood flow increasing brings high blood pressure down.
The clinical treatment that is used for the treatment of essential hypertension, congestive heart failure and various complication of compound valsartan sheet, wherein valsartan is the orally active Angiotensin Receptors antagonistic of non-peptide class, hydrochlorothiazide is a diuretic, both share and can reduce blood pressure light, the moderate primary hypertension patient effectively, and adverse reaction rate is low.Be mainly used in the fully light moderate essential hypertension of controlling blood pressure of treatment single medicine, can take for a long time, do not influence heart rate.
Utilize calcium channel blocker amlodipine, angiotensin receptor blocker valsartan and diuretic hydrochlorothiazide, make compound preparation, give full play to three's complementation, synergism, help to control better patient's blood pressure.This uses a kind of important new selection of poor effect patient after two types of antihypertensive drug therapeutic alliances to those.Existing patent of invention (CN101478956A) discloses two synusia of a kind of amlodipine, valsartan and hydrochlorothiazide combination, constitute by amlodipine layer and valsartan+hydrochlorothiazide layer, come with some shortcomings as a kind of two synusia, two synusia are in preparation process, technology is comparatively complicated, to having relatively high expectations of equipment.The preparation of two synusia need be passed through the secondary tabletting.In this case, may cause sheet press tension, easy disintegrating discharges, the shaping finished product rate is low relatively in the preparation, phenomenons such as sheet is more occur taking, its preparation technology is obviously than the single-layer sheet complexity.
Summary of the invention
For addressing the above problem, the purpose of this utility model is to provide this kind capsule double-layer tablet.
This utility model capsule double-layer tablet comprises capsule body 1 and the active agent formulation of loading in capsule body 1, be single preparations of ephedrine amlodipine sheet 2 and compound preparation valsartan sheet 3, described tablet 2 is the single preparationss of ephedrine that are made of Amlodipine Besylate Tablet and pharmaceutic adjuvant, and described tablet 3 is the compound preparations that are made of principal agent valsartan, hydrochlorothiazide and pharmaceutic adjuvant.
In this utility model, the pharmaceutic adjuvant of indication can be one or more in filler, disintegrating agent, binding agent, the lubricant.
In this utility model capsule, two tablets are housed in each capsule, wherein the amlodipine sheet contains amlodipine 5mg, and the compound valsartan sheet contains valsartan/hydrochlorothiazide 80/12.5mg.
During preparation, this utility model preparation is loaded in the capsule promptly earlier with folk prescription amlodipine sheet and compound valsartan sheet by separately prescription compacting in flakes then, simple for process, can realize that tablet need not through twice pressurized, tablet yield rate height, common tablet machine can be realized.
Description of drawings
Fig. 1 is a front view of the present utility model
Specific embodiment
As shown in Figure 1, amlodipine compound valsartan capsule sheet, form by capsule softgel shell and the medicine that incapsulates inside, the form of the medicine in wherein incapsulating is that folk prescription medicinal tablet 2 and 3. 2 in compound medicine tablet are the single preparationss of ephedrine that are made of amlodipine and excipient substance, and sheet 3 is the compound preparations that are made of principal agent valsartan, hydrochlorothiazide and excipient substance.Particularly, the amlodipine sheet is made up of amlodipine, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, starch, magnesium stearate.The compound valsartan sheet is made up of valsartan, hydrochlorothiazide, crospovidone, microcrystalline Cellulose, alpha-lactose, magnesium stearate.
During making:
(1) amlodipine, microcrystalline Cellulose and the low-substituted hydroxypropyl cellulose of getting recipe quantity distinguished porphyrize, cross 80 mesh sieves, progressively increase behind the abundant mix homogeneously of method by equivalent, with starch slurry (6%) is that binding agent is granulated, dry, granulate, with the magnesium stearate mixing, tabletting promptly gets single preparations of ephedrine amlodipine sheet 2 again.
(2) get the principal agent valsartan and the hydrochlorothiazide of recipe quantity, cross 80 mesh sieves and adjuvant disintegrating agent crospovidone, binding agent microcrystalline Cellulose, filler alpha-lactose, magnesium stearate lubricant mix homogeneously, tabletting promptly gets compound preparation valsartan sheet 3.
(3) microplate 2 and microplate 3 are incapsulated in 1, can obtain amlodipine compound valsartan capsule sheet.
Claims (1)
1. amlodipine compound valsartan capsule, comprise capsule body (1) and load active agent formulation in capsule body (1), be single preparations of ephedrine amlodipine sheet (2) and compound preparation valsartan sheet (3), the principal agent of compound valsartan sheet (3) comprises valsartan and hydrochlorothiazide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010202391149U CN201692349U (en) | 2010-06-22 | 2010-06-22 | Amlodipine polypharmacy valsartan capsule tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010202391149U CN201692349U (en) | 2010-06-22 | 2010-06-22 | Amlodipine polypharmacy valsartan capsule tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201692349U true CN201692349U (en) | 2011-01-05 |
Family
ID=43393591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010202391149U Expired - Lifetime CN201692349U (en) | 2010-06-22 | 2010-06-22 | Amlodipine polypharmacy valsartan capsule tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201692349U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933000A (en) * | 2014-05-06 | 2014-07-23 | 山东新时代药业有限公司 | Azilsartan tablet and preparation method thereof |
-
2010
- 2010-06-22 CN CN2010202391149U patent/CN201692349U/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933000A (en) * | 2014-05-06 | 2014-07-23 | 山东新时代药业有限公司 | Azilsartan tablet and preparation method thereof |
| CN103933000B (en) * | 2014-05-06 | 2021-11-12 | 山东新时代药业有限公司 | Azilsartan tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006649B (en) | Compound preparation of valsartan amlodipine tablet (I) and preparation method thereof | |
| CN101450211A (en) | Composite antihypertensive preparation | |
| RU2015106688A (en) | DRUGS AND METHODS FOR OBTAINING DRUGS FOR USE IN EMPTY DRAGES | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN101249083A (en) | Compound extended release formulation containing amlodipine and metoprolol and preparation | |
| CN101804030B (en) | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof | |
| CN102247376A (en) | Compound solid preparation of valsartan and hydrochlorothiazide, and preparation method thereof | |
| CN102697778B (en) | Valsartan amlodipine compound solid preparation and preparation method thereof | |
| CN201692349U (en) | Amlodipine polypharmacy valsartan capsule tablet | |
| CN102342944A (en) | Medicament composition for treating hypertension | |
| CN101371834B (en) | Medicament composition containing amlodipine besylate and candesartan cilexetil and medicine box | |
| CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
| CN101836963B (en) | Medicinal application preparation for curing hypertension | |
| CN103505460B (en) | A kind of method preparing losartan potassium hydrochlorothiazide composition | |
| CN101797250A (en) | Stable compound preparation | |
| CN101849942B (en) | Medicinal composition for treating hypertension | |
| CN104510738A (en) | Compound composition for treatment of high blood pressure and preparation method thereof | |
| CN101849940B (en) | Medicinal composition for treating hypertension | |
| CN110917170A (en) | Candesartan cilexetil-containing capsule preparation and preparation method thereof | |
| CN101987098A (en) | Valsartan amlodipine medicine composition | |
| CN101313907A (en) | Medicament composition for treating hyperpiesis | |
| CN201668750U (en) | Compound amlodipine, valsartan and hydrochlorothiazide capsule | |
| CN104000821B (en) | Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof | |
| CN103655561A (en) | Pharmaceutical composition containing losartan potassium and amlodipine besylate and preparation method thereof | |
| CN102329283B (en) | Hydrochlorothiazide crystal and candesartan cilexetil hydrochlorothiazide medicinal combination thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhao Xin Lu Document name: Notification of Passing Examination on Formalities |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200107 Address after: 100124 1605, floor 13, building 3, No. 82, East Fourth Ring Middle Road, Chaoyang District, Beijing Patentee after: Beijing Huayao Kechuang Pharmaceutical Technology Development Co., Ltd Address before: 110179 Liaoning province Shenyang Hunnan New Long Street No. 10-1 Co-patentee before: Guan Yi Patentee before: Shenyang Yiling Medicine Technology Co., Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20110105 |